对儿童呼吸道疾病的短效支气管扩展剂进行批判性重新评估
Amelia Licari1,2, Sara Manti3, Francesco Mastellone4
1Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, Pediatric Unit, University of Pavia, Pavia, Italy. amelia.licari@unipv.it.
Italian journal of pediatrics
|May 23, 2024
概括
短效支气管扩展剂,包括短效β2-激动剂和抗胆固醇药,对于儿科呼吸系统疾病至关重要. 本综述综合了当前关于它们的使用,安全性的知识,并确定了最佳治疗的研究缺口.
科学领域:
- 儿科肺病学 儿科肺病学
- 药理学 药理学是指药理学的学科.
- 呼吸系统医学 呼吸系统医学
背景情况:
- 短效支气管扩展剂对于治疗儿科喘和COPD至关重要.
- 了解它们在儿童中的有效性和安全性已经有了显著的进化.
- 关键药物类别包括短效β2-激动剂和短效抗胆固醇药.
研究的目的:
- 为提供对儿童短效支气管扩展剂使用的综合性审查.
- 综合当前关于适应症,适应症和安全性的知识.
- 确定需要进一步研究的领域,以改善儿科呼吸系统护理.
主要方法:
- 文献综述和现有研究的综合.
- 对当前临床指导方针和证据的分析.
- 识别儿科支气管扩展剂治疗中的知识缺口.
主要成果:
- 当前对短效支气管扩展剂在儿科中的有效性和安全性的理解.
- 详细审查儿科使用的说明和禁忌.
- 安全考虑和不良事件概况的总结.
结论:
- 短效支气管扩展剂在儿科呼吸系统管理中仍然至关重要.
- 需要进一步的研究来优化它们的使用,并确保儿童的最大安全性和有效性.
- 基于证据的指导方针对于有效的治疗策略至关重要.
相关概念视频
Antiasthma Drugs: β2-Adrenoceptor Agonists
250
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
250
Drugs Used in Lower Respiratory Disorders: Overview
421
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
421
Inhaled Medications
252
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
252
Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
COPD: Management Using Bronchodilators and Corticosteroids
195
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
195
Antiasthma Drugs: Leukotriene Modifiers
276
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
276


